Abstract: Disclosed is a cannula (CA1 to CA7) for endovascular and/or jugular blood circuit support, comprising: —a proximal portion (PP1 to PP6), —a distal portion (DP1 to DP7) that comprises at least one distal opening (DO1 to DO7), —a lumen portion (LP) that extends from the proximal portion (PP1 to PP6) to the at least one distal opening (DO1 to DO7), and—at least one intermediate portion (IP1 to IP7) that is arranged between the proximal portion (PP1 to PP6) and the distal portion (DP1 to DP7), wherein the intermediate portion (IP1 to IP7) comprises at least one intermediate opening (IO1 to IO7), and wherein the intermediate portion (IP1 to IP7) is configured such that more than 90 volume percent of the fluid flow are drained from the intermediate opening (IO1 to IO7) if a fluid flow within the proximal portion (PP1 to PP6) is directed proximally and such that more than 90 volume percent of the fluid flow are delivered through the at least one distal opening (DO1 to DO7) if a fluid flow within the proximal portion

Abstract: An arrangement (200 to 1200) is provided for transporting a liquid (B) through a cannula system (CS), comprising: a liquid guiding system (LGS) comprising at least three separated portions (SP2a, SP2b, SP3c) which define separate liquid guiding portions of the liquid guiding system (LGS), and a connecting portion (CP2 to CP12) which fluidically connects the at least three separated portions (SP2a, SP2b, SP3c) and which comprises a lumen that branches out into at least two lumens, wherein the liquid guiding system (LGS) is configured to be connected to a pump arrangement (Arr2 to An12) which drives a flow of the liquid (B), and wherein the liquid guiding system (LGS) is configured to be connected to a cannula system (CS) which is adapted to be inserted into a body of a human or of an animal and which comprises an inflow opening and an outflow opening of the liquid guiding system (LGS).

Abstract: A pulmonary artery (PA) via trans-septal to left atrial (LA) percutaneous dual lumen cannulation system which reduce the pressure of the right ventricle provides drainage of pulmonary artery blood with bypassing the lung while return the blood to the Left Atrium (LA) without the need for thoracotomy for a wearable pump less extra corporeal lung assist (pECLA) to remove CO2, pump less extra corporeal membrane oxygenation (ECMO), para-corporeal pump driven CO2 removal, extra corporeal CO2 removal (ECCO2R) pump driven, para-corporeal pump driven membrane oxygenation, or extra corporeal membrane oxygenation (ECMO) with extra-corporeal pump. By establishing percutaneously a shunt with a dual lumen cannula between PA and LA using the PA-LA pressure gradient as the driving force for the blood flow through the drainage lumen, CO2 removal device, or oxygenator and return cannula lumen in the vascular system.

Abstract: A pulmonary artery (PA) via trans-septal to left atrial (LA) percutaneous dual lumen cannulation system which reduce the pressure of the right ventricle provides drainage of pulmonary artery blood with bypassing the lung while return the blood to the Left Atrium (LA) without the need for thoracotomy for a wearable pump less extra corporeal lung assist (pECLA) to remove CO2, pump less extra corporeal membrane oxygenation (ECMO), para-corporeal pump driven CO2 removal, extra corporeal CO2 removal (ECCO2R) pump driven, para-corporeal pump driven membrane oxygenation, or extra corporeal membrane oxygenation (ECMO) with extra-corporeal pump. By establishing percutaneously a shunt with a dual lumen cannula between PA and LA using the PA-LA pressure gradient as the driving force for the blood flow through the drainage lumen, CO2 removal device, or oxygenator and return cannula lumen in the vascular system.

Abstract: The present invention relates a pharmaceutical composition comprising a taxane and an inhibitory compound capable of inhibiting the enzyme acetaldehyde dehydrogenase e.g. disulfiram. The pharmaceutical compositions of the invention can be used to coat medical devices such as implants. Such implant can be an expansible hollow part, having at least one opening, which consists of an elastic biocompatible material that comprises elongated micro-cavities in its surface. Medical devices coated with a pharmaceutical composition of the invention exhibit an enhanced transfer of taxane from the surface of said medical device into the target tissue.

Abstract: The present invention relates to an expansible hollow part, having at least one opening, which consists of an elastic biocompatible material and which comprises at least one biologically active substance and, optionally at least one matrix compound. The invention also provides a method of producing said expansible hollow part, a medical device covered at least partially with said hollow part, a kit-of-parts comprising said hollow part of the invention and the use of said hollow part as a therapeutic device and for protecting a medical device.